Not Yet RecruitingNot Applicable

Swiss Cardiovascular-Kidney-Liver-Metabolic (CKLM) Registry

Switzerland1,500 participantsStarted 2025-07-14

Plain-language summary

The aim of this clinical and exploratory Swiss Cardiovascular-Kidney-Liver-Metabolic (CKLM) Registry is to establish high quality prevalence and incidence database for Cardiovascular-Kidney-Metabolic (CKM) syndrome, its major contributors, and the extent of the respective organ damaged.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * At least 18 years of age * Individuals diagnosed with cardiovascular-kidney-metabolic (CKM) syndrome stages 0 to 3 according to the American Heart Association (AHA) or liver disease defined by any of the following: * For stage 0: Individuals without overweight/obesity, metabolic risk factors (normoglycemia, normotension, normal lipid profile), Chronic kidney disease (CKD), or Cardiovascular disease (CVD) * Individuals with overweight/obesity or dysfunctional adipose tissue, without other metabolic risk factors or CKD * Individuals with metabolic risk factors (hypertriglyceridemia, arterial hypertension, metabolic syndrome, diabetes) or CKD * Subclinical Atherosclerotic cardiovascular disease (ASCVD) or subclinical heart failure (HF) in individuals with excess/dysfunctional adiposity, other metabolic risk factors, or CKD in the clinical assessment\[2\] * Independent of CKM syndrome stages, individual with signs of hepatic steatosis on imaging * Willingness to provide informed consent Exclusion Criteria: * Individuals with CKM syndrome stage 4 according to the AHA \* Individuals with clinical cardiovascular disease including: * History of coronary artery disease, myocardial infarction, coronary artery intervention * History of atrial fibrillation * History of stroke * Symptomatic peripheral artery disease (\>stage I) * History of symptomatic HF * History of HF hospitalisation * Inability to sign informed consent

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Frequency of cardiovascular diseases

Timeframe: At baseline, 6, 12 months and annually up to 10 years

Frequency of kidney diseases

Timeframe: At baseline, 6, 12 months and annually up to 10 years

Frequency of liver diseases

Timeframe: At baseline, 6, 12 months and annually up to 10 years

Frequency of metabolic diseases

Timeframe: At baseline, 6, 12 months and annually up to 10 years

Frequency of microalbuminuria

Timeframe: At baseline, 6, 12 months and annually up to 5 years

Frequency of increased HbA1c

Timeframe: At baseline, 6, 12 months and annually up to 5 years

Assessment of Fib4-score

Timeframe: At baseline, 6, 12 months and annually up to 5 years

Trial details

NCT IDNCT07084688

SponsorUniversity Hospital, Basel, Switzerland

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2040-07

Contact for this trial

Annina Vischer, PD Dr. med.

0041613286630 annina.vischer@usb.ch

View on ClinicalTrials.gov More Cradiovascular-kidney-liver-metabolic (CKLM) Syndrome trials

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

What they're measuring

Frequency of cardiovascular diseases

Timeframe: At baseline, 6, 12 months and annually up to 10 years

Frequency of kidney diseases

Timeframe: At baseline, 6, 12 months and annually up to 10 years

Frequency of liver diseases

Timeframe: At baseline, 6, 12 months and annually up to 10 years

Frequency of metabolic diseases

Timeframe: At baseline, 6, 12 months and annually up to 10 years

Frequency of microalbuminuria

Timeframe: At baseline, 6, 12 months and annually up to 5 years

Frequency of increased HbA1c

Timeframe: At baseline, 6, 12 months and annually up to 5 years

Assessment of Fib4-score

Timeframe: At baseline, 6, 12 months and annually up to 5 years